SG Americas Securities LLC cut its stake in Sanofi (NYSE:SNY) by 21.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,479 shares of the company’s stock after selling 13,801 shares during the period. SG Americas Securities LLC’s holdings in Sanofi were worth $2,466,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the company. Goodwin Daniel L bought a new stake in Sanofi during the second quarter valued at about $239,000. Wellington Management Group LLP bought a new stake in Sanofi during the first quarter valued at about $2,252,000. Stifel Financial Corp raised its stake in Sanofi by 8.6% in the first quarter. Stifel Financial Corp now owns 317,185 shares of the company’s stock valued at $14,362,000 after buying an additional 25,009 shares in the last quarter. Bluestein R H & Co. raised its stake in Sanofi by 7.5% in the first quarter. Bluestein R H & Co. now owns 21,500 shares of the company’s stock valued at $973,000 after buying an additional 1,500 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in Sanofi by 2.2% in the first quarter. Envestnet Asset Management Inc. now owns 463,863 shares of the company’s stock valued at $20,992,000 after buying an additional 10,128 shares in the last quarter. Institutional investors own 9.90% of the company’s stock.

Shares of Sanofi (NYSE:SNY) opened at 48.24 on Thursday. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24. The stock’s 50 day moving average is $47.87 and its 200 day moving average is $46.61. The firm has a market capitalization of $121.16 billion, a price-to-earnings ratio of 11.44 and a beta of 0.88.

Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. The firm’s quarterly revenue was down 2.3% on a year-over-year basis. Equities research analysts forecast that Sanofi will post $3.26 earnings per share for the current fiscal year.

WARNING: “Sanofi (SNY) Shares Sold by SG Americas Securities LLC” was originally published by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/24/sanofi-sny-shares-sold-by-sg-americas-securities-llc.html.

SNY has been the topic of several research analyst reports. BidaskClub upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Cowen and Company restated a “market perform” rating and issued a $52.00 price target (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Friday, June 2nd. Berenberg Bank lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, Argus raised their price target on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Hold” and an average price target of $54.00.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.